Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITIL-168
- Development stage
- Discontinued
- Lead developer
- Instil Bio
- Modality
- Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ITIL-168 was an investigational, autologous cell therapy composed of tumor-infiltrating lymphocytes (TILs) derived from each patient's own digested and cryopreserved tumor tissue. The therapy was designed to offer an unrestricted T-cell receptor repertoire, aiming to harness the patient’s immune system for antitumor activity. ITIL-168 was manufactured using a proprietary process developed by Instil Bio to maximize the diversity of TILs and provide scheduling flexibility for both patients and physicians. It was primarily developed for advanced (unresectable or metastatic) cutaneous melanoma, particularly in patients who have relapsed after or are refractory/intolerant to PD-1 inhibitor therapies. Clinical studies demonstrated promising response rates in this population. The clinical development programs for ITIL-168 were discontinued by Instil Bio as of December 2022.
- Other names
- autologous tumor infiltrating lymphocytes ITIL-168
02
Targets
pMHC (Peptide-MHC complex family)
Beyond the preview
Go deeper on ITIL-168.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITIL-168.